Orion Tong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Orion Tong has a total of 440 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Peter Fairfax
Department of Oncology, University of Oxford, Oxford, UK
17 shared publications - Chelsea Alice Taylor
University of Oxford
11 shared publications - Robert Aerwyn Watson
Department of Oncology, University of Oxford, Oxford, UK
10 shared publications - Mark Ross Middleton
Department of Oncology, University of Oxford, Oxford, UK
9 shared publications - Martin Little
Department of Oncology, University of Oxford, Oxford, UK
8 shared publications - Bo Sun
Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
6 shared publications
Latest Publications
- Open Access
Lymphocyte Stability Following Immune Checkpoint Blockade Is Coupled to Mitochondrial Haplogroup and Clinical Outcome in Advanced Melanoma
Summary: Early biomarkers of durable response to immune checkpoint blockade (ICB) are urgently needed. We identify lymphocyte stability (LS) – preservation of peripheral lymphocyte counts after one cycle of ICB – as an on-treatment predictor of overall survival (OS) in metastatic melanoma (MM): patients with unstable lymphocyte counts (LS-U; post-ICB/baseline ≤0.8) have markedly increased risk of death. Metabolic profiling of patient T cells demonstrates ICB enhancement of mitochondrial bioenergetics, whilst CD8+ T cells from LS-U patients mount an exaggerated transcriptional response to ICB incorporating upregulation of mitochondrial pathways. Given these findings we assessed the relationship of LS with mitochondrial haplogroup, revealing carriage of haplogroup T (HG-T), present in ∼10% of white British individuals, is associated with both LS-U and impaired OS, with mediation analysis implicating LS mediation. HG-T carriers have higher CD8+ T-cell pre-treatment mitochondrially encoded transcript abundance and, in paired scRNA-seq data, fewer progenitor-exhausted cells, ICB hyperresponsivity, apoptotic program induction and reduced clonal persistence – consistent with baseline mitochondrial priming. These findings position LS as a clinically accessible marker of ICB outcome linked to inherited mitochondrial variation. Highlights: - Lymphocyte stability is a pan-cancer predictor of survival and durable response following immune checkpoint blockade - ICB elicits coordinated mitochondrial transcriptional and functional responses in T cells - LS-U mediates the link between mitochondrial HG-T and poor overall survival following checkpoint immunotherapy - HG-T CD8+ T cells are transcriptionally primed at baseline but show enhanced apoptosis and reduced clonal persistence after ICB
Open AccessLymphocyte Stability Following Immune Checkpoint Blockade Is Coupled to Mitochondrial Haplogroup and Clinical Outcome in Advanced Melanoma
Summary: Early biomarkers of durable response to immune checkpoint blockade (ICB) are urgently needed. We identify lymphocyte stability (LS) – preservation of peripheral lymphocyte counts after one cycle of ICB – as an on-treatment predictor of overall survival (OS) in metastatic melanoma (MM): patients with unstable lymphocyte counts (LS-U; post-ICB/baseline ≤0.8) have markedly increased risk of death. Metabolic profiling of patient T cells demonstrates ICB enhancement of mitochondrial bioenergetics, whilst CD8+ T cells from LS-U patients mount an exaggerated transcriptional response to ICB incorporating upregulation of mitochondrial pathways. Given these findings we assessed the relationship of LS with mitochondrial haplogroup, revealing carriage of haplogroup T (HG-T), present in ∼10% of white British individuals, is associated with both LS-U and impaired OS, with mediation analysis implicating LS mediation. HG-T carriers have higher CD8+ T-cell pre-treatment mitochondrially encoded transcript abundance and, in paired scRNA-seq data, fewer progenitor-exhausted cells, ICB hyperresponsivity, apoptotic program induction and reduced clonal persistence – consistent with baseline mitochondrial priming. These findings position LS as a clinically accessible marker of ICB outcome linked to inherited mitochondrial variation. Highlights: - Lymphocyte stability is a pan-cancer predictor of survival and durable response following immune checkpoint blockade - ICB elicits coordinated mitochondrial transcriptional and functional responses in T cells - LS-U mediates the link between mitochondrial HG-T and poor overall survival following checkpoint immunotherapy - HG-T CD8+ T cells are transcriptionally primed at baseline but show enhanced apoptosis and reduced clonal persistence after ICB
- Open Access
- 7 September 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e016050
Anti-CMV IgG titer determines organ-specific protection toward immune checkpoint blockade-induced toxicities
Background: Immune-related adverse events (irAEs) post-immune checkpoint blockade (ICB) are a leading cause of patient morbidity. Robust peripheral biomarkers of irAEs are required to improve patient stratification to existing treatment regimens, and these are currently lacking. Seropositivity for human cytomegalovirus (CMV) is associated with protection against severe (grade 3+) irAEs post-ICB; however, the impact of infection on systemic immunity is highly variable. Here, in a prospectively recruited pan-cancer ICB-treated cohort (n=472 patients), we investigate a novel relationship between the relative baseline titer of anti-CMV IgG antibody and organ-specific protection against irAEs. Methods: Peripheral blood samples were collected from 472 patients prior to and following one cycle of ICB. CMV serotyping was performed on plasma, while flow cytometry and single-cell RNA/V(D)J sequencing were performed on peripheral blood mononuclear cells. Bulk RNA-sequencing was performed on sorted CD8 + T cells. Serological and phenotyping data were integrated with long-term clinical follow-up of response and irAEs. Results: In CMV seropositive patients, whereas anti-CMV IgG antibody level demonstrates stability over years, high pretreatment titer is independently associated with reduced all-organ grade 3+ irAEs. This pan-organ association subdivides into organ-specific effects; protection against non-colitis irAEs being observed only in those with an above median titer of anti-CMV IgG antibody (P High titer vs CMV −=2.1×10 −4 ), whereas CMV-related protection against colitis is unrelated to titer (P Low titer =0.0012, P High titer =0.0031). We demonstrate that anti-CMV IgG antibody titer is robustly coupled to peripheral immune subset composition, with higher anti-CMV IgG titer associated with elevated CD4 + and CD8 + T cell cytotoxicity and effector cell expansion. Conversely, CMV seropositivity is associated with generally reduced circulating T regs cells irrespective of titer. Furthermore, we find exacerbated T cell receptor repertoire skewing toward the largest clones in High Titer individuals, with reduced survival of these clones following ICB treatment. Conclusions: This work reinforces the importance of CMV in modulating ICB-induced irAEs, revealing a complex relationship between the degree of humoral anti-CMV immunity and organ-specific protection, while further highlighting the clinical utility of CMV serology in predicting ICB-induced irAEs.
- 7 September 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e016050
Open AccessAnti-CMV IgG titer determines organ-specific protection toward immune checkpoint blockade-induced toxicities
Background: Immune-related adverse events (irAEs) post-immune checkpoint blockade (ICB) are a leading cause of patient morbidity. Robust peripheral biomarkers of irAEs are required to improve patient stratification to existing treatment regimens, and these are currently lacking. Seropositivity for human cytomegalovirus (CMV) is associated with protection against severe (grade 3+) irAEs post-ICB; however, the impact of infection on systemic immunity is highly variable. Here, in a prospectively recruited pan-cancer ICB-treated cohort (n=472 patients), we investigate a novel relationship between the relative baseline titer of anti-CMV IgG antibody and organ-specific protection against irAEs. Methods: Peripheral blood samples were collected from 472 patients prior to and following one cycle of ICB. CMV serotyping was performed on plasma, while flow cytometry and single-cell RNA/V(D)J sequencing were performed on peripheral blood mononuclear cells. Bulk RNA-sequencing was performed on sorted CD8 + T cells. Serological and phenotyping data were integrated with long-term clinical follow-up of response and irAEs. Results: In CMV seropositive patients, whereas anti-CMV IgG antibody level demonstrates stability over years, high pretreatment titer is independently associated with reduced all-organ grade 3+ irAEs. This pan-organ association subdivides into organ-specific effects; protection against non-colitis irAEs being observed only in those with an above median titer of anti-CMV IgG antibody (P High titer vs CMV −=2.1×10 −4 ), whereas CMV-related protection against colitis is unrelated to titer (P Low titer =0.0012, P High titer =0.0031). We demonstrate that anti-CMV IgG antibody titer is robustly coupled to peripheral immune subset composition, with higher anti-CMV IgG titer associated with elevated CD4 + and CD8 + T cell cytotoxicity and effector cell expansion. Conversely, CMV seropositivity is associated with generally reduced circulating T regs cells irrespective of titer. Furthermore, we find exacerbated T cell receptor repertoire skewing toward the largest clones in High Titer individuals, with reduced survival of these clones following ICB treatment. Conclusions: This work reinforces the importance of CMV in modulating ICB-induced irAEs, revealing a complex relationship between the degree of humoral anti-CMV immunity and organ-specific protection, while further highlighting the clinical utility of CMV serology in predicting ICB-induced irAEs.
- Open Access
- 17 July 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (10) , 2202-2218
Seq-ing the Truth
Key Points: Baseline vein single-nucleus RNA sequencing identified molecular programs associated with arteriovenous fistula nonmaturation. Failed arteriovenous fistulas showed endothelial interferon and TNF/NF-κB inflammatory signaling. Failed arteriovenous fistulas showed reduced smooth muscle bioenergetic and proliferative programs. Background: Arteriovenous fistula (AVF) nonmaturation remains common. Although attention has historically focused on postoperative processes, evidence suggests that preanastomotic vessel wall signaling, at AVF creation, contributes to subsequent AVF outcomes. The objective was to integrate quantitative baseline biochemistry and vein histology with single-nucleus RNA sequencing (snRNA-seq) from intraoperative tissue and relate structural, cellular, and molecular features to subsequent AVF maturation. Methods: In a prospective, single-center, observational cohort, 17 consecutive patients undergoing first AVF creation contributed venous tissue for snRNA-seq. Maturation was adjudicated using clinical and/or ultrasound criteria. snRNA-seq used donor-level pseudobulk differential expression within annotated cell types with preranked Hallmark pathway enrichment; serum IL-6 (where available) was included. Results: Nine AVFs matured, and eight failed to mature. Histologic intima–media thickness did not differ by outcome. An intact endothelial layer was more frequent in matured AVFs but did not reach significance (78% versus 25%; P = 0.06). Serum IL-6 did not differ ( P = 0.69). Brachial artery flow at assessment was markedly higher in matured AVFs (mean 973 versus 146 ml/min; P < 0.001). Endothelial cells from failed-to-mature AVFs showed strong enrichment of iIFN- α / γ responses and TNF α /NF-κB signaling (false discovery rate α /NF-κB signaling. Conclusions: Baseline vessel-wall transcriptomes were associated with endothelial inflammatory priming and reduced vascular smooth muscle bioenergetic/proliferative programs in AVFs that subsequently failed to mature. This may inform early risk stratification.
- 17 July 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (10) , 2202-2218
Open AccessSeq-ing the Truth
Key Points: Baseline vein single-nucleus RNA sequencing identified molecular programs associated with arteriovenous fistula nonmaturation. Failed arteriovenous fistulas showed endothelial interferon and TNF/NF-κB inflammatory signaling. Failed arteriovenous fistulas showed reduced smooth muscle bioenergetic and proliferative programs. Background: Arteriovenous fistula (AVF) nonmaturation remains common. Although attention has historically focused on postoperative processes, evidence suggests that preanastomotic vessel wall signaling, at AVF creation, contributes to subsequent AVF outcomes. The objective was to integrate quantitative baseline biochemistry and vein histology with single-nucleus RNA sequencing (snRNA-seq) from intraoperative tissue and relate structural, cellular, and molecular features to subsequent AVF maturation. Methods: In a prospective, single-center, observational cohort, 17 consecutive patients undergoing first AVF creation contributed venous tissue for snRNA-seq. Maturation was adjudicated using clinical and/or ultrasound criteria. snRNA-seq used donor-level pseudobulk differential expression within annotated cell types with preranked Hallmark pathway enrichment; serum IL-6 (where available) was included. Results: Nine AVFs matured, and eight failed to mature. Histologic intima–media thickness did not differ by outcome. An intact endothelial layer was more frequent in matured AVFs but did not reach significance (78% versus 25%; P = 0.06). Serum IL-6 did not differ ( P = 0.69). Brachial artery flow at assessment was markedly higher in matured AVFs (mean 973 versus 146 ml/min; P < 0.001). Endothelial cells from failed-to-mature AVFs showed strong enrichment of iIFN- α / γ responses and TNF α /NF-κB signaling (false discovery rate α /NF-κB signaling. Conclusions: Baseline vessel-wall transcriptomes were associated with endothelial inflammatory priming and reduced vascular smooth muscle bioenergetic/proliferative programs in AVFs that subsequently failed to mature. This may inform early risk stratification.
- Open Access
Anti-CMV IgG Titre Determines Organ-Specific Protection Towards Immune Checkpoint Blockade Induced Toxicities
Seropositivity for human cytomegalovirus (CMV) is associated with protection against severe (Grade 3+) immune-related adverse events (irAEs) post Immune Checkpoint Blockade (ICB). Here, in a prospectively recruited pan-cancer ICB-treated cohort (n=448 patients), we identify a novel relationship between the relative baseline titre of anti-CMV IgG antibody and organ-specific protection against irAEs. In CMV seropositive patients, whereas anti-CMV IgG antibody level is stable over years, increased pre-treatment titre is independently associated with reduced all-organ Grade 3+ irAEs. This pan-organ association sub-divides into organ-specific effects; protection against non-colitis irAEs being observed only in those with an above median titre of anti-CMV IgG antibody ( P High titre vs. CMV − =2×10 −5 ), whereas CMV-related protection against colitis is unrelated to titre ( P Low titre =0.0016, P High titre =0.0012). We demonstrate that anti-CMV IgG antibody titre is robustly related to peripheral immune subset composition, with higher anti-CMV IgG titre associated with elevated CD4 + and CD8 + T cell cytotoxicity and effector cell expansion. Conversely, CMV seropositivity is associated with general reduced circulating Tregs irrespective of titre. This work reinforces the importance of CMV in modulating ICB-induced irAEs, revealing a complex relationship between degree of humoral anti-CMV immunity and organ-specific protection, whilst further highlighting the clinical utility of CMV serology in predicting ICB induced irAEs.
Open AccessAnti-CMV IgG Titre Determines Organ-Specific Protection Towards Immune Checkpoint Blockade Induced Toxicities
Seropositivity for human cytomegalovirus (CMV) is associated with protection against severe (Grade 3+) immune-related adverse events (irAEs) post Immune Checkpoint Blockade (ICB). Here, in a prospectively recruited pan-cancer ICB-treated cohort (n=448 patients), we identify a novel relationship between the relative baseline titre of anti-CMV IgG antibody and organ-specific protection against irAEs. In CMV seropositive patients, whereas anti-CMV IgG antibody level is stable over years, increased pre-treatment titre is independently associated with reduced all-organ Grade 3+ irAEs. This pan-organ association sub-divides into organ-specific effects; protection against non-colitis irAEs being observed only in those with an above median titre of anti-CMV IgG antibody ( P High titre vs. CMV − =2×10 −5 ), whereas CMV-related protection against colitis is unrelated to titre ( P Low titre =0.0016, P High titre =0.0012). We demonstrate that anti-CMV IgG antibody titre is robustly related to peripheral immune subset composition, with higher anti-CMV IgG titre associated with elevated CD4 + and CD8 + T cell cytotoxicity and effector cell expansion. Conversely, CMV seropositivity is associated with general reduced circulating Tregs irrespective of titre. This work reinforces the importance of CMV in modulating ICB-induced irAEs, revealing a complex relationship between degree of humoral anti-CMV immunity and organ-specific protection, whilst further highlighting the clinical utility of CMV serology in predicting ICB induced irAEs.
- Open Access
- 29 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Genetic determinants of monocyte splicing are enriched for disease susceptibility loci
Insights into variation in monocyte context-specific splicing and transcript usage are limited. Here, we perform paired gene and transcript QTL mapping across distinct immune states using RNA sequencing data of monocytes isolated from a cohort of 185 healthy Europeans incubated alone or in the presence of interferon gamma (IFN-γ) or lipopolysaccharide (LPS). We identify regulatory variants for 5749 genes and 8727 transcripts, with 291 context-specific transcript QTL colocalizing with GWAS loci. Notable disease relevant associations include IFN-γ specific transcript QTL at COVID-19 severity locus rs10735079, where allelic variation modulates context-specific splicing of OAS1, and at rs4072037, a risk allele for gastro-esophageal cancer, which associates with context-specific splicing of MUC1. We use DNA methylation data from the same cells to demonstrate overlap between methylation QTL and causal context-specific expression QTL, permitting inference of the direction of effect. Finally, we identify a subset of expression QTL that uncouple genes from proximally acting regulatory networks, creating ‘co-expression QTL’ with different allele-specific correlation networks. Our findings highlight the interplay between context and genetics in the regulation of the monocyte gene expression and splicing, revealing putative mechanisms of diverse disease risk alleles including for COVID-19 and cancer.
- 29 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Open AccessGenetic determinants of monocyte splicing are enriched for disease susceptibility loci
Insights into variation in monocyte context-specific splicing and transcript usage are limited. Here, we perform paired gene and transcript QTL mapping across distinct immune states using RNA sequencing data of monocytes isolated from a cohort of 185 healthy Europeans incubated alone or in the presence of interferon gamma (IFN-γ) or lipopolysaccharide (LPS). We identify regulatory variants for 5749 genes and 8727 transcripts, with 291 context-specific transcript QTL colocalizing with GWAS loci. Notable disease relevant associations include IFN-γ specific transcript QTL at COVID-19 severity locus rs10735079, where allelic variation modulates context-specific splicing of OAS1, and at rs4072037, a risk allele for gastro-esophageal cancer, which associates with context-specific splicing of MUC1. We use DNA methylation data from the same cells to demonstrate overlap between methylation QTL and causal context-specific expression QTL, permitting inference of the direction of effect. Finally, we identify a subset of expression QTL that uncouple genes from proximally acting regulatory networks, creating ‘co-expression QTL’ with different allele-specific correlation networks. Our findings highlight the interplay between context and genetics in the regulation of the monocyte gene expression and splicing, revealing putative mechanisms of diverse disease risk alleles including for COVID-19 and cancer.
- Open Access
- 25 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (30) , eadu3461
Defining the genetic determinants of CD8 + T cell receptor repertoire in the context of immune checkpoint blockade
The relationship between genetic variation and CD8 + T cell receptor (TCR) repertoire usage in patients receiving immune checkpoint blockade (ICB) therapy for cancer is unexplored. We have conducted a genome-wide and human leukocyte antigen (HLA)–focused analysis of CD8 + TCR repertoire to identify genetic determinants of variable gene (V-gene) and CDR3 K -nucleotide oligomer usage from samples taken before and after ICB ( n = 250). We identify 11 cis and 10 trans V-gene associations, primarily to the MHC, that meet genome-wide significance. TCR clones containing HLA associated V-genes were less stable across treatment, while, at the single-cell level, genetically associated clones demonstrate subset enrichment and increased tumor reactivity expression profiles. Notably, patients with HLA-matched TCR clones demonstrate improved overall survival. Our work indicates a complex relationship between genotype and TCR repertoire in the context of ICB treatment, with implications for understanding factors relating to therapeutic response and patient outcomes.
- 25 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (30) , eadu3461
Open AccessDefining the genetic determinants of CD8 + T cell receptor repertoire in the context of immune checkpoint blockade
The relationship between genetic variation and CD8 + T cell receptor (TCR) repertoire usage in patients receiving immune checkpoint blockade (ICB) therapy for cancer is unexplored. We have conducted a genome-wide and human leukocyte antigen (HLA)–focused analysis of CD8 + TCR repertoire to identify genetic determinants of variable gene (V-gene) and CDR3 K -nucleotide oligomer usage from samples taken before and after ICB ( n = 250). We identify 11 cis and 10 trans V-gene associations, primarily to the MHC, that meet genome-wide significance. TCR clones containing HLA associated V-genes were less stable across treatment, while, at the single-cell level, genetically associated clones demonstrate subset enrichment and increased tumor reactivity expression profiles. Notably, patients with HLA-matched TCR clones demonstrate improved overall survival. Our work indicates a complex relationship between genotype and TCR repertoire in the context of ICB treatment, with implications for understanding factors relating to therapeutic response and patient outcomes.
- Open Access
- 23 April 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (7) , 2350-2364
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
Cytomegalovirus (CMV) is a globally endemic latent herpes virus that profoundly impacts T cell immunity. We investigated the oncological consequences of CMV infection across 341 prospectively recruited patients receiving immune checkpoint blockade (ICB) for melanoma. CMV+ patients with metastatic melanoma (MM) have higher lymphocyte counts, reduced neutrophil to lymphocyte ratio and divergent CD8+ T cell gene expression. Combination anti-CTLA-4/anti-PD-1 ICB, but not single-agent anti-PD-1 ICB, induces cytotoxicity and CMV-associated gene expression in CD8+ T cells from CMV− patients. Correspondingly, overall survival was independent of CMV serostatus in combination anti-CTLA-4/anti-PD-1 ICB recipients (CMV+ hazard ratio for death: 1.02, P = 0.92), whereas CMV+ single-agent anti-PD-1 ICB recipients had improved overall survival (CMV+ hazard ratio for death: 0.37, P < 0.01), a finding also seen in CMV+ adjuvant single-agent anti-PD-1 ICB recipients (CMV+ hazard ratio for recurrence: 0.19, P = 0.03). We identify TBX21, encoding T-bet, as a transcriptional driver of CMV-associated CD8+ T cell gene expression, finding that TBX21 expression is predictive of overall survival (hazard ratio: 0.62, P = 0.026). CMV+ patients unexpectedly show reduced cumulative incidence of grade 3+ immune-related adverse events at 6 months (0.30 versus 0.52, P = 2.2 × 10−5), with lower incidence of colitis (P = 7.8 × 10−4) and pneumonitis (P = 0.028), an effect replicated in non-melanoma ICB recipients (n = 58, P = 0.044). Finally, we find reduced CMV seropositivity rates in patients with MM compared with UK Biobank controls (odds ratio: 0.52, P = 1.8 × 10−4), indicating CMV seropositivity may protect against MM. Specifically, patients with BRAF-mutated MM are less likely to be CMV+ (odds ratio = 2.2, P = 0.0054), while CMV− patients present 9 yr earlier with BRAF wild-type MM (P = 1.3 × 10−4). This work reveals an interaction between CMV infection, MM development according to BRAF status and response to ICB, while demonstrating CMV infection is protective against severe ICB immune-related adverse events, highlighting the potential importance of previous infection history and chronic immune activation in MM development and immunotherapy outcomes.
- 23 April 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (7) , 2350-2364
Open AccessCMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade
Cytomegalovirus (CMV) is a globally endemic latent herpes virus that profoundly impacts T cell immunity. We investigated the oncological consequences of CMV infection across 341 prospectively recruited patients receiving immune checkpoint blockade (ICB) for melanoma. CMV+ patients with metastatic melanoma (MM) have higher lymphocyte counts, reduced neutrophil to lymphocyte ratio and divergent CD8+ T cell gene expression. Combination anti-CTLA-4/anti-PD-1 ICB, but not single-agent anti-PD-1 ICB, induces cytotoxicity and CMV-associated gene expression in CD8+ T cells from CMV− patients. Correspondingly, overall survival was independent of CMV serostatus in combination anti-CTLA-4/anti-PD-1 ICB recipients (CMV+ hazard ratio for death: 1.02, P = 0.92), whereas CMV+ single-agent anti-PD-1 ICB recipients had improved overall survival (CMV+ hazard ratio for death: 0.37, P < 0.01), a finding also seen in CMV+ adjuvant single-agent anti-PD-1 ICB recipients (CMV+ hazard ratio for recurrence: 0.19, P = 0.03). We identify TBX21, encoding T-bet, as a transcriptional driver of CMV-associated CD8+ T cell gene expression, finding that TBX21 expression is predictive of overall survival (hazard ratio: 0.62, P = 0.026). CMV+ patients unexpectedly show reduced cumulative incidence of grade 3+ immune-related adverse events at 6 months (0.30 versus 0.52, P = 2.2 × 10−5), with lower incidence of colitis (P = 7.8 × 10−4) and pneumonitis (P = 0.028), an effect replicated in non-melanoma ICB recipients (n = 58, P = 0.044). Finally, we find reduced CMV seropositivity rates in patients with MM compared with UK Biobank controls (odds ratio: 0.52, P = 1.8 × 10−4), indicating CMV seropositivity may protect against MM. Specifically, patients with BRAF-mutated MM are less likely to be CMV+ (odds ratio = 2.2, P = 0.0054), while CMV− patients present 9 yr earlier with BRAF wild-type MM (P = 1.3 × 10−4). This work reveals an interaction between CMV infection, MM development according to BRAF status and response to ICB, while demonstrating CMV infection is protective against severe ICB immune-related adverse events, highlighting the potential importance of previous infection history and chronic immune activation in MM development and immunotherapy outcomes.
- Open Access
Defining the genetic determinants of CD8 + T cell receptor repertoire in the context of immune checkpoint blockade
CD8 + T cells play a central role in the cancer response to immune checkpoint blockade (ICB) treatment, with activity predicated upon antigen recognition by the associated T cell receptor (TCR) repertoire. The contribution of genetic variation to this in cancer treatment is under-explored. We have conducted a genome-wide and human leukocyte antigen (HLA)-focused analysis of CD8 + T cell TCR repertoire to identify genetic determinants of variable gene (V-gene) and CDR3 K-mer usage from samples taken prior to and after ICB treatment (n=250). We find 11 genome-wide significant cis associations and 10 trans associations, primarily to the HLA, with V-gene usage meeting permuted P-value thresholds. Notably, TCR clones containing V-genes associated with HLA were less likely to be persistent across treatment. In a single-cell experiment, we find cells with HLA-matched TCR clones have increased tumor reactivity expression profiles and patients with HLA-matched TCR clones have improved overall survival. Our work indicates a complex relationship between genotype and TCR repertoire in the context of treatment with ICB, which has novel implications for understanding determinants of treatment response and patient outcomes. One Sentence Summary: TCR repertoire is strongly associated with specific HLA alleles in cancer patients, but immune checkpoint blockade influences this association.
Open AccessDefining the genetic determinants of CD8 + T cell receptor repertoire in the context of immune checkpoint blockade
CD8 + T cells play a central role in the cancer response to immune checkpoint blockade (ICB) treatment, with activity predicated upon antigen recognition by the associated T cell receptor (TCR) repertoire. The contribution of genetic variation to this in cancer treatment is under-explored. We have conducted a genome-wide and human leukocyte antigen (HLA)-focused analysis of CD8 + T cell TCR repertoire to identify genetic determinants of variable gene (V-gene) and CDR3 K-mer usage from samples taken prior to and after ICB treatment (n=250). We find 11 genome-wide significant cis associations and 10 trans associations, primarily to the HLA, with V-gene usage meeting permuted P-value thresholds. Notably, TCR clones containing V-genes associated with HLA were less likely to be persistent across treatment. In a single-cell experiment, we find cells with HLA-matched TCR clones have increased tumor reactivity expression profiles and patients with HLA-matched TCR clones have improved overall survival. Our work indicates a complex relationship between genotype and TCR repertoire in the context of treatment with ICB, which has novel implications for understanding determinants of treatment response and patient outcomes. One Sentence Summary: TCR repertoire is strongly associated with specific HLA alleles in cancer patients, but immune checkpoint blockade influences this association.
- Open Access
Cytomegalovirus infection protects against metastatic melanoma and modulates oncological outcome and toxicity to checkpoint immunotherapy
Summary Paragraph: The relationship between chronic viral infection and cancer response to immune checkpoint blockade (ICB) is poorly understood. Cytomegalovirus (CMV) infection is globally endemic and causes severe disease in the immunocompromised. In immunocompetent individuals the clinical effects of CMV infection are an area of active investigation. Here, in analysis of 396 patients receiving ICB for cancer, we investigate the oncological and immunological consequences of CMV seropositivity. We find that infection with CMV leads to profound skewing of CD8 + T cell subsets towards an effector phenotype, divergence in gene expression, increased total lymphocyte count and reduced neutrophil:lymphocyte ratio. These differences are associated with immunologically distinct responses to ICB in patients with metastatic melanoma (MM). We identify a gene set highly-associated with CMV infection which is robustly induced by combination ICB (anti-CTLA-4 + anti-PD-1, cICB) but not by single-agent anti-PD-1 (sICB) in CMV seronegative individuals. Consequently, CMV seropositivity is associated with prolonged Overall Survival (OS) in those treated with sICB (HR 0.49, P.01) whereas there is no observed survival association of CMV following cICB treatment (HR 0.95, P=.82). We demon-strate these CMV-determined divergent effects are driven by expression of TBX21 , encoding the transcription factor T-bet. Expression of TBX21 predicts OS across all patients (HR 0.67, P=0.013 for above-median expression), with durable response to ICB associated with induction of expanded TBX21 expressing CD8 + clones. Unexpectedly, we find CMV infection is associated with reduced cumulative incidence of Grade 3+ immune related adverse events (irAEs) at 6 months (0.31 vs. 0.53, P=2.1×10 −5 ), notably lowering incidence of colitis (P=.00095) and pneumonitis (P=.026), with infected patients requiring fewer steroids or second line immunosuppressants. Finally we link CMV infection to protection against MM, demonstrating lower seropositivity rates in patients with MM, but not early Stage II/III disease, compared to population controls from the UK biobank (OR 0.53, P=.00016). CMV protection is contingent upon melanoma BRAF mutation status, with CMV being associated with reduced development of MM in BRAF mutated patients and later presentation of BRAF wild-type MM. This work reveals a previously unrecognised interaction between CMV infection, melanoma muta-tional state, development of metastatic disease and response to ICB, as well as demonstrating CMV infection protects against ICB irAEs, underpinning the importance of prior infection history and chronic immune activation in development of MM and outcomes to immunotherapy. We anticipate other immunosensitive cancers may show similar interactions between chronic viral infection and response to ICB.
Open AccessCytomegalovirus infection protects against metastatic melanoma and modulates oncological outcome and toxicity to checkpoint immunotherapy
Summary Paragraph: The relationship between chronic viral infection and cancer response to immune checkpoint blockade (ICB) is poorly understood. Cytomegalovirus (CMV) infection is globally endemic and causes severe disease in the immunocompromised. In immunocompetent individuals the clinical effects of CMV infection are an area of active investigation. Here, in analysis of 396 patients receiving ICB for cancer, we investigate the oncological and immunological consequences of CMV seropositivity. We find that infection with CMV leads to profound skewing of CD8 + T cell subsets towards an effector phenotype, divergence in gene expression, increased total lymphocyte count and reduced neutrophil:lymphocyte ratio. These differences are associated with immunologically distinct responses to ICB in patients with metastatic melanoma (MM). We identify a gene set highly-associated with CMV infection which is robustly induced by combination ICB (anti-CTLA-4 + anti-PD-1, cICB) but not by single-agent anti-PD-1 (sICB) in CMV seronegative individuals. Consequently, CMV seropositivity is associated with prolonged Overall Survival (OS) in those treated with sICB (HR 0.49, P.01) whereas there is no observed survival association of CMV following cICB treatment (HR 0.95, P=.82). We demon-strate these CMV-determined divergent effects are driven by expression of TBX21 , encoding the transcription factor T-bet. Expression of TBX21 predicts OS across all patients (HR 0.67, P=0.013 for above-median expression), with durable response to ICB associated with induction of expanded TBX21 expressing CD8 + clones. Unexpectedly, we find CMV infection is associated with reduced cumulative incidence of Grade 3+ immune related adverse events (irAEs) at 6 months (0.31 vs. 0.53, P=2.1×10 −5 ), notably lowering incidence of colitis (P=.00095) and pneumonitis (P=.026), with infected patients requiring fewer steroids or second line immunosuppressants. Finally we link CMV infection to protection against MM, demonstrating lower seropositivity rates in patients with MM, but not early Stage II/III disease, compared to population controls from the UK biobank (OR 0.53, P=.00016). CMV protection is contingent upon melanoma BRAF mutation status, with CMV being associated with reduced development of MM in BRAF mutated patients and later presentation of BRAF wild-type MM. This work reveals a previously unrecognised interaction between CMV infection, melanoma muta-tional state, development of metastatic disease and response to ICB, as well as demonstrating CMV infection protects against ICB irAEs, underpinning the importance of prior infection history and chronic immune activation in development of MM and outcomes to immunotherapy. We anticipate other immunosensitive cancers may show similar interactions between chronic viral infection and response to ICB.
- Open Access
- 11 July 2024
- Published by Springer Nature in Research Square
Genetic determinants of monocyte splicing are enriched for disease susceptibility loci including for COVID-19
Insights into variation in monocyte context-specific splicing and transcript usage are limited. We have performed paired gene and transcript QTL mapping across distinct immune states using RNA-seq of monocytes isolated from a cohort of 185 healthy Europeans incubated alone or in the presence of IFNγ or lipopolysaccharide (LPS). We identify regulatory variants to 5,749 genes and 8,727 transcripts, with 291 context-specific tQTL colocalising with GWAS loci (PP.H4 > 0.8). Notable disease relevant associations (PP.H4 > 0.99) include IFNγ specific tQTL at COVID-19 severity locus rs10735079, where allelic variation modulates context-specific splicing of OAS1, and at rs4072037, a risk allele for gastro-esophageal cancer, which associates with context-specific splicing of MUC1. Assessment of DNA methylation from the same cells demonstrated frequent overlap between mQTL and causal context-specific eQTL, frequently permitting inference of the direction of effect. Finally, we identify a subset of eQTL that uncouple genes from proximally acting regulatory networks, creating ‘co-expression QTL’ (coExQTL) with differential allele-specific correlation networks. Our findings highlight the interplay between context and genetics in the regulation of the monocyte gene expression and splicing, revealing putative mechanisms of diverse disease risk alleles including for COVID-19 and cancer.
- 11 July 2024
- Published by Springer Nature in Research Square
Open AccessGenetic determinants of monocyte splicing are enriched for disease susceptibility loci including for COVID-19
Insights into variation in monocyte context-specific splicing and transcript usage are limited. We have performed paired gene and transcript QTL mapping across distinct immune states using RNA-seq of monocytes isolated from a cohort of 185 healthy Europeans incubated alone or in the presence of IFNγ or lipopolysaccharide (LPS). We identify regulatory variants to 5,749 genes and 8,727 transcripts, with 291 context-specific tQTL colocalising with GWAS loci (PP.H4 > 0.8). Notable disease relevant associations (PP.H4 > 0.99) include IFNγ specific tQTL at COVID-19 severity locus rs10735079, where allelic variation modulates context-specific splicing of OAS1, and at rs4072037, a risk allele for gastro-esophageal cancer, which associates with context-specific splicing of MUC1. Assessment of DNA methylation from the same cells demonstrated frequent overlap between mQTL and causal context-specific eQTL, frequently permitting inference of the direction of effect. Finally, we identify a subset of eQTL that uncouple genes from proximally acting regulatory networks, creating ‘co-expression QTL’ (coExQTL) with differential allele-specific correlation networks. Our findings highlight the interplay between context and genetics in the regulation of the monocyte gene expression and splicing, revealing putative mechanisms of diverse disease risk alleles including for COVID-19 and cancer.